Summary
Protein binding of phenytoin was assessed in one patient with dialysis encephalopathy before and after haemodialysis. Phenytoin concentrations were measured by radioimmunoassay and continuous ultrafiltration was used to assess phenytoin binding. At a serum concentration of 60 µmol.1−1 the percentage of phenytoin bound to serum albumin was considerably lower in the patient serum (79.95% predialysis; 92.09% postdialysis) than that in three normal sera (97.90±0.17%). Analysis of Scatchard plots indicated two classes of binding sites. In class I both the affinity and capacity for binding phenytoin were reduced in the pre and post-dialysis serum, whereas in class II the capacity of the uraemic serum was increased although the intrinsic association constant was greatly reduced. It was concluded that in vivo haemodialysis is associated with large fluctuations in the protein binding of phenytoin, in which the concentration of endogenous dialysible metabolites are strongly implicated.
This is a preview of subscription content, log in via an institution to check access.
References
The Boston Collaborative Drug Surveillance Program: Diphenylhydantoin side-effects and serum albumin levels. Clin. Pharmacol. Ther.14, 529–532 (1973)
Blum, M. R., Riegelman, S., Becker, C. E.: Altered protein binding of diphenylhydantoin in uremic plasma. N. Engl. J. Med.286, 109 (1972)
Hooper, W. D., Bochner, F., Eadie, M. J., Tyrer, J. H.: Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin. Pharmacol. Ther.15, 276–282 (1974)
Andreasen, F.: Protein binding of drugs in serum from patients with acute anuria. Acta Pharmacol. Toxicol. (Kbh.)34, 284 (1974)
Campion, D. S., Olsen, R.: Measurement of drug displacement by continuous ultrafiltration. J. Pharm. Sci.63, 249–252 (1974)
Paxton, J. W., Rowell, F. J., Ratcliffe, J. G.: Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay. J. Immunol. Methods10, 317–327 (1976)
Scatchard, G.: The attraction of proteins for small molecules and ions. Ann. N. Y. Acad. Sci.51, 660–672 (1949)
Dromgoole, S. H.: The effect of haemodialysis on the binding capacity of albumin. Clin. Chim. Acta46, 469–472 (1973)
Soltys, B. J., Hsia, J. C.: Fatty acid enhancement of human serum albumin binding properties. J. Biol. Chem.252, 4043–4048 (1977)
Geigler, R., Shoeman, D. W., Azarnoff, D. L.: Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology12, 160–165 (1974)
Grossman, S. B., Yap, S. H., Shafritz, D. A.: Influence of chronic renal failure on protein synthesis and albumin metabolism in rat liver. J. Clin. Invest.59, 869–878 (1977)
Boobis, S. W.: The alteration of plasma albumin in relation to decreased drug binding in uremia. Clin. Pharmacol. Ther.22, 147–152 (1977)
Elliott, H. L., Dryburgh, F., Fell, G. S., Sabet, S., Macdougall, A. I.: Aluminium toxicity during regular haemodialysis. Br. Med. J.1978/I, 1101
Kaehny, W. D., Alfrey, A. C., Holman, R. E., Shorr, W. J.: Aluminium transfer during haemodialysis. Kidney Int.12, 361–365 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steele, W.H., Lawrence, J.R., Elliott, H.L. et al. Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy. Eur J Clin Pharmacol 15, 69–71 (1979). https://doi.org/10.1007/BF00563560
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00563560